Animal experiments have shown that inhibiting GCGR signaling improves branched-chain amino acid metabolism, enhances cardiac function after myocardial infarction, and attenuates cardiac remodeling by modulating the TAK1/p38 MAPK and KLF15/BCATm pathways (19). This evidence concerns the gene BCAT2 and myocardial infarction.